Plaque Psoriasis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Plaque Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Plaque Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Plaque Psoriasis Pipeline Report
- DelveInsight’s Plaque Psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75 + pipeline therapies for Plaque Psoriasis treatment.
- The leading companies working in the Plaque Psoriasis Market include Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others.
- Promising Plaque Psoriasis Pipeline Therapies in the various stages of development include Tapinarof, Bimekizumab, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), DUR-928 Topical Solution, and others.
- October 2023: Amgen announced a study of Phase 3 clinical trials for Apremilast. The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis. A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast (AMG 407) in Japanese Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis.
- October 2023: LEO Pharma announced a study of Phase 3 clinical trials for LEO 90100. This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment. This study is phase 3, randomised, prospective, investigator-blinded, active-controlled, parallel group, multicentre trial to evaluate the efficacy and safety of 4 weeks treatment with LEO 90100 compared with Daivobet® ointment. Eligible participants will be randomised in a 1:1 ratio to either LEO 90100 or Daivobet® ointment treatment.
Request a sample and discover the recent advances in Plaque Psoriasis Treatment Drugs @ Plaque Psoriasis Pipeline Report
In the Plaque Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Plaque Psoriasis Overview
Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and associated with abnormalities of other systems. Plaque psoriasis is the commonest clinical type of psoriasis. Even though the condition is not life-threatening, it is difficult to treat and response rates vary widely.
Find out more about Plaque Psoriasis Therapeutics Assessment @ Plaque Psoriasis Preclinical and Discovery Stage Products
Plaque Psoriasis Emerging Drugs Profile
- ARQ-151: Arcutis Biotherapeutics
- ABY-035: Affibody
- AK101: Akeso Biopharma
Plaque Psoriasis Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the Plaque Psoriasis therapies. The Plaque Psoriasis companies which have their Plaque Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, Arcutis Biotherapeutics.
DelveInsight’s Plaque Psoriasis pipeline report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Plaque Psoriasis Pipeline Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Learn more about the emerging Plaque Psoriasis Pipeline Therapies @ Plaque Psoriasis Clinical Trials Assessment
Scope of the Plaque Psoriasis Pipeline Report
- Coverage- Global
- Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Plaque Psoriasis Companies- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and others.
- Plaque Psoriasis Pipeline Therapies- Tapinarof, Bimekizumab, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), DUR-928 Topical Solution, and others.
Dive deep into rich insights for new drugs for Plaque Psoriasis Treatment, Visit @ Plaque Psoriasis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Plaque Psoriasis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Plaque Psoriasis – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- ARQ-151: Arcutis Biotherapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ABY-035: Affibody
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- CT303: GC Cell
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Plaque Psoriasis Key Companies
- Plaque Psoriasis Key Products
- Plaque Psoriasis- Unmet Needs
- Plaque Psoriasis- Market Drivers and Barriers
- Plaque Psoriasis- Future Perspectives and Conclusion
- Plaque Psoriasis Analyst Views
- Plaque Psoriasis Key Companies
- Appendix
For further information on the Plaque Psoriasis Pipeline therapeutics, reach out to Plaque Psoriasis Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/plaque-psoriasis-market
){kind=link}